Scientific reasoning for booster vaccine doses for COVID-19 is under examination but the priority is to ensure complete vaccination of the eligible population with both doses, the government said on Thursday.
In a press briefing, in which the government also announced the detection of two cases of the Omicron variant of COVID-19 in India, Health Joint Secretary Lav Agarwal said, "The scientific reasoning for boosters at what timing for which vaccine all that is under examination."
"Our priority is the complete task of administering both vaccines and this is the strategy which will give us the best dividend," he said while responding to a question.
On the significance of vaccination in view of the new variant, NITI Aayog member (Health) Dr V K Paul said despite this new challenge, vaccination remains the most critical tool.
"We are fortunate that we have the tool (vaccination) in plenty and there is no doubt that coverage of vaccines has to increase. Look at the big picture, we have this tool and we must protect every eligible individual with this tool," he said.
"We are benefited by two doses and people should get the second dose as soon as possible. The decision on duration between doses is based on scientific data and local data in a systematic manner, and there is no change in the present duration," Paul said.
On breakthrough infections, he said, "We do not see any red flag in breakthrough infections, and we look into it periodically. In the past, we have shown that breakthrough rates are very low and we will provide more information."
On contact tracing approach of individuals detected with Omicron in India, Dr Sujeet Kumar Singh, Director, National Centre for Disease Control, said the government is tracing three types of contacts - primary, secondary and tertiary.
"Remote contacts are also being traced...it comes in the state government's domain and state surveillance officers are cooperating for it. In this case -- (two cases of Omicron) -- the primary, secondary and tertiary contacts have been traced," he said.
Explaining INSACOG's strategy, Singh said, "We have 289 sentinel sites and the samples, which we get from these sentinel sites, we do genomic sequencing on a weekly basis, and any super spreader events we find, clustering of cases, there we do genomic sequencing to ascertain if any new variant has emerged...the new dimension is the airport screening".
As of now, flights have come to nine airports, from where genome samples have been collected and tested, and 30 international airports have been sensitised about any travelling or in transit passengers coming from "at-risk" countries, he said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)